Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Go back to Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain| Management Of Environmental Solutions & Technology (NASDAQ: MESO) | Delayed: 15.50 +1.13 (7.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.37 | 52 Week High | $10.89 | |||
| Open | $14.95 | 52 Week Low | $3.50 | |||
| Day High | $15.66 | P/E | N/A | |||
| Day Low | $14.95 | EPS | $0.00 | |||
| Volume | 400,427 | |||||
| MESABI TRUST (NYSE: MSB) | Delayed: 24.54 -0.24 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.78 | 52 Week High | $11.74 | |||
| Open | $24.54 | 52 Week Low | $3.00 | |||
| Day High | $25.33 | P/E | 15.53 | |||
| Day Low | $24.38 | EPS | $1.58 | |||
| Volume | 130,393 | |||||
